ClinicalTrials.gg
CompletedNCT02034019Updated Jan 31, 2020Results posted

Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

A Phase 3 interventional study of Dexamethasone and Punctum Plug in Post Ocular Surgical Inflammation and Pain, sponsored by Ocular Therapeutix, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-31.

Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies testing dexamethasone in Pain — 9 open to participants now, 10 under way, 2 of them phase 3. Dexamethasone · Pain.

Enrollment
3rd of 64
247 · median 89
Started
2014
with 7 others
Phase 3
9 of 64
2 open now
Registered
21st of 64
by date
Lead sponsor
3 of 64
Ocular Therapeutix, Inc.

Among the 64 studies testing dexamethasone in Pain, this one is the 3rd largest by enrollment, is one of 8 that started in 2014, is one of 9 in phase 3, and was the 21st registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

9 of the 64 studies testing dexamethasone in Pain are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing dexamethasone in Pain, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.

03

Conditions studied

  • Post Ocular Surgical Inflammation and Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber intraocular lens
  • Has a potential post-operative pinhole corrected Snellen VA of at least 20/200 or better in both eyes

Exclusion criteria

Exclusion Criteria:

  • Any intraocular inflammation in the study eye present during the screening slit lamp examination
  • Score greater than "0" on the Ocular Pain Assessment in the study eye at Screening
  • Any intraocular inflammation in the study eye present during the screening slit lamp examination
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
247 participants (actual)

Study arms

  • Active comparator
    OTX-DP (Dexamethasone Punctum Plug)

    Resorbable hydrogel drug delivery vehicle containing dexamethasone

    Drug: Dexamethasone · Drug: Punctum Plug

  • Placebo comparator
    PVPP (Placebo Punctum Plug)

    Resorbable hydrogel drug delivery vehicle containing no drug

    Drug: Punctum Plug

Interventions

06

What researchers measure

Primary outcomes

  1. Absence of Cells in Anterior Chamber of the Study Eye

    Time frame: Day 14

  2. Absence of Pain in Study Eye

    Time frame: Day 8

07

Results

Posted Jan 31, 2020

Participant flow

Participant flow — Overall Study
MilestoneOTX-DP (Dexamethasone Punctum Plug)PVPP (Placebo Punctum Plug)
Started16483
Completed16381
Not completed12

Outcome measures

PrimaryAbsence of Cells in Anterior Chamber of the Study Eye
Time frame:
Day 14
Reported as:
Count of participants · Participants
Absence of Cells in Anterior Chamber of the Study Eye
ParticipantsOTX-DP (Dexamethasone Punctum Plug)PVPP (Placebo Punctum Plug)
Absence of Cells in Anterior Chamber of the Study Eye5412
PrimaryAbsence of Pain in Study Eye
Time frame:
Day 8
Reported as:
Count of participants · Participants
Absence of Pain in Study Eye
ParticipantsOTX-DP (Dexamethasone Punctum Plug)PVPP (Placebo Punctum Plug)
Absence of Pain in Study Eye13136

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTX-DP (Dexamethasone Punctum Plug)—0/162 (0%)37/162 (22.8%)
PVPP (Placebo Punctum Plug)—1/84 (1.2%)31/84 (36.9%)
Most frequent serious events
Most frequent serious events
EventOTX-DP (Dexamethasone Punctum Plug)PVPP (Placebo Punctum Plug)
hypopyonEye disorders0/1621/84
Most frequent other events
Most frequent other events
EventOTX-DP (Dexamethasone Punctum Plug)PVPP (Placebo Punctum Plug)
inflammationEye disorders37/16231/84

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OTX-DP (Dexamethasone Punctum Plug)PVPP (Placebo Punctum Plug)Total
<=18 years000
Between 18 and 65 years561672
>=65 years10867175
Sex: Female, Male
Sex: Female, Male(Participants)OTX-DP (Dexamethasone Punctum Plug)PVPP (Placebo Punctum Plug)Total
Female10344147
Male6139100
08

Study locations

1 site
  • Texan Eye / Keystone Research, Ltd.
    Austin, Texas 78731, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Dec 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2014
First posted
Jan 13, 2014
Start
Feb 2014
Primary completionActual
Dec 2014
CompletionActual
Feb 2015
Results first posted
Jan 31, 2020
Last update
Jan 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02034019
Responsible party
Sponsor
First posted
Jan 13, 2014
Start date
Feb 2014
Primary completion
Dec 2014
Completion
Feb 2015
Results posted
Jan 31, 2020
Last update
Jan 31, 2020

Study contacts

Clinical Project Manager
study director · Ocular Therapeutix

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion